Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)

被引：25

作者：

Cornelissen, Robin ^{[1
]}

Prelaj, Arsela ^{[2
,3
]}

Sun, Sophie ^{[4
]}

Baik, Christina ^{[5
]}

Wollner, Mirjana ^{[6
]}

Haura, Eric B. ^{[7
]}

Mamdani, Hirva ^{[8
,9
]}

Riess, Jonathan W. ^{[10
,11
]}

Cappuzzo, Federico ^{[12
]}

Garassino, Marina C. ^{[13
]}

Heymach, John V. ^{[14
]}

Socinski, Mark A. ^{[15
]}

Leu, Szu-Yun ^{[16
]}

Bhat, Gajanan ^{[16
]}

Lebel, Francois ^{[16
]}

Le, Xiuning ^{[14
]}

机构：

[1] Erasmus MC Canc Inst, Pulm Med, Rotterdam, Netherlands

[2] Fdn Ist Ricovero & Cura Carattere Sci IRCCS, Ist Nazl Tumori Milano, Med Oncol, Milan, Italy

[3] Politecn Milan, Dept Elect Informat & Bioengn, Milan, Italy

[4] British Columbia Canc Ctr, Med Oncol, Vancouver, BC, Canada

[5] Seattle Canc Ctr Alliance, Seattle, WA USA

[6] Rambam Hlth Care Campus, Med Oncol, Haifa, Israel

[7] H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol, Tampa, FL USA

[8] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI USA

[9] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[10] Univ Calif Davis, Sch Med, Div Hematol & Oncol, Dept Internal Med, Sacramento, CA USA

[11] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA

[12] Natl Canc Inst IRCCS Regina Elena, Dept Oncol, Rome, Italy

[13] Univ Chicago, Hematol Oncol Sect, Dept Med, Knapp Ctr Biomed Discovery, Chicago, IL USA

[14] Univ Texas MD Anderson Canc Ctr Houston, Dept Thorac Head & Neck Med Oncol, Houston, TX USA

[15] AdventHlth Canc Inst, Thorac Oncol Program, Orlando, FL USA

[16] Spectrum Pharmaceut, Res Dev, Irvine, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 08期

关键词：

KINASE DOMAIN; ANTITUMOR-ACTIVITY; SOMATIC MUTATIONS; CANCER; EGFR; HM781-36B; INHIBITOR;

D O I：

10.1016/j.jtho.2023.03.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1031 / 1041

页数：11

共 50 条

[21] Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial
Sun, Lu
Wang, Juan
Shao, Linlin
Yuan, Chenglu
Zhao, Hongguo
Li, Daqi
Wang, Zhencheng
Han, Panpan
Yu, Yafei
Xu, Miao
Zhao, Hongyu
Qiu, Jihua
Zhou, Hai
Liu, Xinguang
Hou, Yu
Peng, Jun
Hou, Ming
LANCET HAEMATOLOGY, 2021, 8 (04): : E289 - E298
[22] Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations
Janne, P.
Wang, M.
Mitchell, P.
Fang, J.
Nian, W.
Chiu, C.
Zhou, J.
Zhao, Y.
Su, W.
Camidge, D. R.
Yang, T.
Zhu, V.
Millward, M.
Fan, Y.
Huang, W.
Cheng, Y.
Jiang, L.
Brungs, D.
Bazhenova, L.
Lee, C. K.
Gao, B.
Qi, S.
Yu, X.
Deng, C.
Chen, K.
Ye, X.
Zheng, L.
Yang, Z.
Yang, J. C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S874 - S874
[23] Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1+Arm 2 Results from a Multicenter, Open-Label Phase 2 Study
Fowler, Nathan
Nastoupil, Loretta
de Vos, Sven
Knapp, Mark
Flinn, Ian W.
Chen, Robert W.
Advani, Ranjana H.
Bhatia, Sumeet
Martin, Peter
Mena, Raul
Suzuki, Samuel
Beaupre, Darrin M.
Neuenburg, Jutta K.
Palomba, M. Lia
BLOOD, 2016, 128 (22)
[24] A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19)2 2
Kim, Yu Jung
Kim, Soyeon
Kim, Tae Min
Suh, Koung Jin
Kim, Miso
Kim, Se Hyun
Keam, Bhumsuk
Kim, Dong-Wan
Lee, Jong Seok
Heo, Dae Seog
LUNG CANCER, 2024, 194
[25] A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of solid tumors harboring specific HER2-activating mutations (DESTINY-PanTumor01).
Li, Bob T.
Meric-Bernstam, Funda
Puvvada, Soham D.
Rowbottom, Jacqui
Jolliffe, Darren
Gustavson, Mark
Mendoza-Naranjo, Ariadna
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[26] Comparison of the effectiveness of 2 shockwave therapy protocols for the treatment of vascular erectile dysfunction: a randomized, multicenter, open-label, noninferiority, phase 4 clinical trial
Corredor, Hector A.
Sandoval-Salinas, Carolina
Martinez, Juan M.
Barba, Jorge
Patron, Francisco
JOURNAL OF SEXUAL MEDICINE, 2025,
[27] Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial
Fang, Wenfeng
Zhao, Yuanyuan
Huang, Yan
Zhang, Yaxiong
Hong, Shaodong
Huang, Yihua
Zhao, Hongyun
Yang, Yunpeng
Zhao, Shen
Chen, Gang
Zhou, Huaqiang
Ma, Yuxiang
Zhou, Ningning
Zhang, Li
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[28] Efficacy and Safety of Darunavir/Ritonavir at 48 Weeks in Treatment-naive, HIV-1-infected Adolescents Results From a Phase 2 Open-label Trial (DIONE)
Flynn, Patricia
Komar, Svitlana
Blanche, Stephane
Giaquinto, Carlo
Noguera-Julian, Antoni
Welch, Steven
Lathouwers, Erkki
Van de Casteele, Tom
Kakuda, Thomas N.
Opsomer, Magda
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (09) : 940 - 945
[29] Apatinib combined with docetaxel and platinum as neoadjuvant treatment for triple-negative/HER2-positive breast cancer: A randomized, open-label, multicenter, phase 2 trial
Liu, Yunjiang
Zhang, Shuo
CANCER RESEARCH, 2020, 80 (04)
[30] Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
Kowdley, Kris V.
Lawitz, Eric
Crespo, Israel
Hassanein, Tarek
Davis, Mitchell N.
DeMicco, Michael
Bernstein, David E.
Afdhal, Nezam
Vierling, John M.
Gordon, Stuart C.
Anderson, Jane K.
Hyland, Robert H.
Dvory-Sobol, Hadas
An, Di
Hindes, Robert G.
Albanis, Efsevia
Symonds, William T.
Berrey, M. Michelle
Nelson, David R.
Jacobson, Ira M.
LANCET, 2013, 381 (9883): : 2100 - 2107

← 1 2 3 4 5 →